News Releases

October 23, 2025

New Data from Merck Animal Health Demonstrates that Intranasal Vaccination Against Bovine Coronavirus with BOVILLIS® NASALGEN®-C (Lyophilisate and Solvent for Suspension for Cattle) Significantly Improves Production in Veal Calves

Vaccinated calves showed fewer lung lesions and achieved a significantly higher body weight than unvaccinated calves Rahway, N.J., October 23, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the presentation of new data […]

September 26, 2025

Merck Animal Health Presents New Data Demonstrating the Safety, Efficacy and Quick Onset of Injectable Formulation of BRAVECTO® (fluralaner) at World Small Animal Veterinary Association Congress

Additional educational symposia offer the latest information on vector-borne diseases, infectious diseases and treatment and prevention protocols Rahway, NJ, September 26, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced it will present multiple […]

September 25, 2025

Merck Animal Health Strengthens Its Dedication to Rabies Elimination with 7 Millionth Vaccine Donation Through the Afya Program

RAHWAY, N.J., Sept. 26, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced it has donated more than seven million NOBIVAC® rabies vaccines through the Company’s Afya Program, since it was founded. “Communities experiencing ongoing […]

September 24, 2025

New Study Confirms Rapid Action of PROTAZIL® (1.56% diclazuril) Antiprotozoal Pellets for the Treatment of Equine Protozoal Myeloencephalitis (EPM)

Diclazuril reaches therapeutic levels within 12 hours, reinforcing the drug as a first-line EPM treatment option RAHWAY, N.J., September 24, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the results of a new […]

September 12, 2025

Merck Animal Health Presented New Data on NUMELVI® (atinvicitinib) Tablets for Dogs and MOMETAMAX ULTRA® (gentamicin, posaconazole, and mometasone furoate otic suspension) for Dogs at the 2025 European Veterinary Dermatology Congress

RAHWAY, N.J., September 12, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced new data demonstrating the safety and efficacy of NUMELVI® (atinvicitinib) Tablets for Dogs and MOMETAMAX ULTRA® (gentamicin, posaconazole, and mometasone furoate […]

August 19, 2025

Vets and Pet-Owners See Gaps in Flea and Tick Prevention, Highlighting Need for Year-Round Care, New Merck Animal Health Global Survey Finds

Data show pet owners face difficulties with consistent compliance, while veterinarians worry about inconsistent or incorrect medication administration In the U.S. Two-thirds of veterinarians note that most pet owners do not follow year-round treatment plan, despite evidence that fleas and tick are present during all seasons RAHWAY, N.J., August 19, 2025 – Merck Animal Health, […]

August 18, 2025

Merck Animal Health Presents New Data Highlighting Commitment to the Development and Study of Parasite Prevention and Treatment for Dogs at the 2025 World Association for the Advancement of Veterinary Parasitology Congress

Data to showcase depth and breadth of the BRAVECTO® (fluralaner) portfolio including the injectable and oral endectocide combination formulations RAHWAY, N.J., August 18, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced it will […]

July 24, 2025

European Commission Approves NUMELVI™ (atinvicitinib) Tablets for Dogs

NUMELVI from Merck Animal Health is the First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Treatment of Pruritus Associated with Allergic Dermatitis Including Atopic Dermatitis and Treatment of Clinical Manifestations of Atopic Dermatitis in Dogs RAHWAY, N.J., July 24, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United […]

July 18, 2025

Merck Animal Health Announces FDA Approval of EXZOLT™ (fluralaner oral solution) for Chickens, the First Systemic Treatment for Northern Fowl Mites

Innovative oral solution offers a safe and effective approach to combat northern fowl mite infestations in poultry RAHWAY, N.J., July 18, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and […]

July 10, 2025

FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health

12-Month Parasiticide Treatment for Dogs Offers Unrivaled Duration of Flea and Tick Protection Compared to Existing Products RAHWAY, N.J., July 10, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and […]